JEROME B ZELDIS
Medical Practice in Princeton, NJ
License number
New Jersey 25MA06502000
Issued Date
Dec 11, 1996
Expiration Date
Jun 30, 2017
Category
Medical Examiners
Type
Medical Doctor
Address
Address
Princeton, NJ
Personal information
See more information about JEROME B ZELDIS at radaris.comName
Address
Phone
151 Library Pl, Princeton, NJ 08540
Princeton, NJ
151 Library Pl, Princeton, NJ 08540
157 Christopher Dr, Princeton, NJ 08540
Professional information
Methods For Treating Cancers Using Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
US Patent:
2008013, Jun 5, 2008
Filed:
May 5, 2004
Appl. No.:
10/557302
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Markian S. Jaworsky - Hopewell NJ, US
George W. Muller - Bridgewater NJ, US
Louise M. Cameron - Nazareth PA, US
Roger Shen-Chu Chen - Edison NJ, US
Manohar T. Saindane - Monmouth Junction NJ, US
Markian S. Jaworsky - Hopewell NJ, US
George W. Muller - Bridgewater NJ, US
Louise M. Cameron - Nazareth PA, US
Roger Shen-Chu Chen - Edison NJ, US
Manohar T. Saindane - Monmouth Junction NJ, US
International Classification:
A61K 31/454, A61P 35/00
US Classification:
514323
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods And Compositions Using Selective Cytokine Inhibitory Drugs For Treatment And Management Of Cancers And Other Diseases
US Patent:
2008026, Oct 30, 2008
Filed:
May 5, 2004
Appl. No.:
11/579351
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Assignee:
CELGENE CORPORATION - Warren NJ
International Classification:
A61K 38/20, A61K 39/395, A61K 38/16, A61K 31/56, A61K 31/5377, A61K 31/517, A61K 31/352, A61K 38/21, A61P 35/00, A61K 31/404, A61K 38/13, A61K 31/65, A61K 31/69, A61K 31/4353, A61K 31/704
US Classification:
424 852, 4241521, 4241381, 4241581, 4241411, 514 12, 514178, 514182, 5142345, 5142664, 4241331, 4241451, 514453, 514415, 514 9, 514154, 514 64, 514283, 514 34, 424 854, 514416
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods For Treating Diffuse Large B-Cell Lymphoma With 3-(4-Amino-1-Oxo-1,3-Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione In Combination With Second Active Agents
US Patent:
2013030, Nov 14, 2013
Filed:
Jul 15, 2013
Appl. No.:
13/942232
Inventors:
Jerome B. Zeldis - Princeton NJ, US
International Classification:
A61K 31/454, A61K 45/06, A61K 39/395
US Classification:
4241331
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods Of Using 4-(Amino)-2-(2,6-Dioxo(3-Piperidly))-Isoindoline-3-Dione For The Treatment Of Myelodysplastic Syndromes
US Patent:
7863297, Jan 4, 2011
Filed:
Nov 12, 2007
Appl. No.:
11/985032
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Assignee:
Celgene Corporation - Summit NJ
International Classification:
A61K 31/445
US Classification:
514323
Abstract:
Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods For Treatment Of Chronic Uveitis Using Cyclopropyl-N-{2-[(1S)-1-(3-Ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)Ethyl]-3-Oxoisoindoline-4-Yl}Carboxamide
US Patent:
7354948, Apr 8, 2008
Filed:
Nov 6, 2003
Appl. No.:
10/534325
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Assignee:
Celgene Corporation - Summit NJ
International Classification:
A61K 31/40, A01N 43/38
US Classification:
514411, 514412, 514416, 514417
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods For Treating Cutaneous Lupus Using Aminoisoindoline Compounds
US Patent:
2007015, Jul 5, 2007
Filed:
Dec 21, 2006
Appl. No.:
11/645319
Inventors:
Jerome Zeldis - Princeton NJ, US
Patricia Rohane - Florham Park NJ, US
Peter Schafer - Somerset NJ, US
Patricia Rohane - Florham Park NJ, US
Peter Schafer - Somerset NJ, US
International Classification:
A61K 31/454, A61K 31/4035
US Classification:
514323000, 514417000
Abstract:
Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID™), 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (REVLIMID®), or cyclopropyl 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, alone or alternatively, in combination with a second active agent.
Methods Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione For Treatment Of Mantle Cell Lymphomas
US Patent:
2010006, Mar 18, 2010
Filed:
Nov 19, 2009
Appl. No.:
12/621502
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Assignee:
Celgene Corporation - Summit NJ
International Classification:
A61K 39/395, A61K 31/454, A61K 31/573, A61P 35/00
US Classification:
4241331, 514323, 514171
Abstract:
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Methods Of Treating Multiple Myeloma Using Melphalan, Prednisone And Lenalidomide
US Patent:
2012003, Feb 9, 2012
Filed:
Oct 19, 2011
Appl. No.:
13/276867
Inventors:
Jerome B. Zeldis - Princeton NJ, US
International Classification:
A61K 31/56, A61P 35/00
US Classification:
514171
Abstract:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Methods Of Treating Myelodysplastic Syndromes Using Lenalidomide
US Patent:
8404717, Mar 26, 2013
Filed:
Mar 24, 2011
Appl. No.:
13/070761
Inventors:
Jerome B. Zeldis - Princeton NJ, US
Assignee:
Celgene Corporation - Summit NJ
International Classification:
A61K 31/47, A61K 31/445
US Classification:
514323, 514 58, 514319, 514327
Abstract:
Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
Methods And Compositions Using Thalidomide For The Treatment And Management Of Central Nervous System Disorders Or Diseases
US Patent:
2005018, Aug 18, 2005
Filed:
Dec 23, 2004
Appl. No.:
11/022065
Inventors:
Jerome Zeldis - Princeton NJ, US
Herbert Faleck - West Orange NJ, US
Peter Schafer - Somerset NJ, US
Herbert Faleck - West Orange NJ, US
Peter Schafer - Somerset NJ, US
International Classification:
A61K031/454
US Classification:
514323000
Abstract:
Methods of treating, preventing and/or managing central nervous system disorders, such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) and related syndromes are disclosed. Specific methods encompass the administration of thalidomide, or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.